Stoneridge Investment Partners LLC Invests $689,000 in Solventum Corporation $SOLV

Stoneridge Investment Partners LLC bought a new position in shares of Solventum Corporation (NYSE:SOLV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,065 shares of the company’s stock, valued at approximately $689,000.

Several other institutional investors have also bought and sold shares of SOLV. Independent Franchise Partners LLP lifted its holdings in shares of Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after acquiring an additional 2,456,451 shares during the period. State Street Corp lifted its holdings in Solventum by 2.0% during the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock valued at $502,759,000 after purchasing an additional 124,490 shares during the last quarter. Davis Selected Advisers boosted its position in Solventum by 12.7% in the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after buying an additional 702,461 shares in the last quarter. Boston Partners grew its stake in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after buying an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Solventum by 20.0% during the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock worth $362,375,000 after buying an additional 763,308 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on SOLV shares. BTIG Research raised their price objective on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Mizuho set a $113.00 price objective on Solventum in a research report on Thursday, August 6th. Wells Fargo & Company decreased their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings upgraded Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 17th. Finally, Stifel Nicolaus upped their price target on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Solventum currently has an average rating of “Hold” and an average target price of $91.64.

Solventum Stock Performance

SOLV stock opened at $88.53 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. The company has a 50 day moving average price of $80.11 and a 200 day moving average price of $74.67. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $90.00. The stock has a market capitalization of $15.07 billion, a PE ratio of 10.82, a price-to-earnings-growth ratio of 1.14 and a beta of 0.60.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Analysts forecast that Solventum Corporation will post 7.22 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.